OTC Markets EXMKT - Delayed Quote USD

Transgene SA (TRGNF)

0.7000

0.0000

(0.00%)

At close: April 15 at 4:00:00 PM EDT

Availability of Transgene’s 2024 Universal Registration Document (URD)

Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that the French version of its 2024 Universal Registration Document was filed with the French Financial Markets Authority (Autorité des marchés financiers – AMF) on April 10, 2025, under number D.25-0243. This document, available on the AMF’s website (www.amf-france.org), can be viewed and downloaded (in PDF format in French and English, and in ESEF form

GlobeNewswire 5 days ago

TRGNF
0.00%
Transgene Appoints Chief Technical Officer (CTO) to Power Future Innovations

Dr. Simone Steiner will focus on improving the manufacturing processes of individualized immunotherapies based on myvac® platform Strasbourg, France, April 1, 2025, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, is pleased to announce the appointment of Simone Steiner, PhD, as Chief Technical Officer (CTO), effective immediately. Dr. Steiner will be responsible for manufacturing and process dev

GlobeNewswire 14 days ago

TRGNF
0.00%
Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ̶ Strong Outlook for 2025

2024 Full-year results and business update Clinical proof of principle obtained in Phase I adjuvant head and neck cancer trial with individualized cancer vaccine TG4050 ̶ Further data on 24-month follow-up for all patients of the Phase I part expected in Q2 2025 Randomization in Phase II part of the Phase I/II trial evaluating TG4050 in head and neck cancer patients due to be completed in Q4 2025 New trial with individualized cancer vaccine planned to start in Q4 2025 in a second indication Busi

GlobeNewswire 19 days ago

TRGNF
0.00%
Transgene to Participate in Upcoming Investor Meetings

Strasbourg (France), March 11, 2025, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will meet institutional investors during the upcoming editions of: Investor Access Event (by Investor Access), on April 1, 2025, in ParisLife Sciences Conference (by Van Lanschot Kempen), on April 2, 2025, in Amsterdam Next scheduled financial communications: The 2024 Ful

GlobeNewswire last month

TRGNF
0.00%
Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts

Strasbourg (France), February 6, 2025, 5:45 p.m. CET—Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, confirms that, in accordance with the provisions of the Attractiveness Act (“Loi d’Attractivité” – French Law No. 2024-537 of June 13, 2024), its shares are eligible for inclusion in the PEA-PME investment scheme*. As a result, Transgene (TNG) shares can be included or retained within this savings plan, which is

GlobeNewswire 2 months ago

TRGNF
0.00%
Transgene to Participate in the Biomed Forum Investor Conference

Strasbourg (France), January 21, 2025, 5:45 PM CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announced that its management team will participate in the upcoming edition of the Biomed Forum, a conference for institutional investors. Organized by AllInvest Securities, this event will take place on February 4, 2025, in Paris. *** About Transgene Transgene (Euronext: TNG) is a biotechnology company fo

GlobeNewswire 2 months ago

TRGNF
0.00%
Transgene Announces Financial Calendar for 2025

Strasbourg (France), January 14, 2025, 5:45 p.m. CET—Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces its financial reporting dates for 2025: March 27, 2025: 2024 Fiscal Year Results April 24, 2025: First Quarter 2025 Financial Results May 15, 2025: Annual Shareholders' Meeting September 16, 2025: First Half 2025 Financial Results November 4, 2025: Third Quarter 2025 Financial Results *** About Transge

GlobeNewswire 2 months ago

TRGNF
0.00%
Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2024

Strasbourg, January 7, 2025 – 06:00 pm CET Under the liquidity contract entrusted by Transgene to Natixis Oddo BHF SCA, as of December 31, 2024, the following resources were managed through the liquidity account: 359,661 shares€ 80,653.30 In the second half of 2024, a total of: Purchases 250,777 shares€ 243,947.381,154 market transactionsSales229 905 shares€ 230,275.171,081 market transactions It is recalled that when the liquidity program was initially established in 2016, the following resourc

GlobeNewswire 3 months ago

TRGNF
0.00%
Transgene Reports Business, Pipeline and Financial Update for Q3 2024

TG4050: Promising Phase I data to be presented at SITC 2024 providing clinical proof of principle in adjuvant head and neck cancer setting Financial visibility confirmed into Q4 2025 Strasbourg, France, November 7, 2024, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today provides its business update and financial position for the quarter ending September 30, 2024. Key events and upcoming mile

GlobeNewswire 5 months ago

TRGNF
0.00%
Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024

Compelling 24.1-month median follow-up data presented at SITC 2024 showed that all patients treated with TG4050 after completion of an adjuvant standard of care remain disease-free TG4050 induced specific and sustained immune responses. A Phase II part is now enrolling patients internationally to build on this promising outcome Strasbourg, France & Tokyo, Japan, November 7, 2024, 5:45 p.m. CET — Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherap

GlobeNewswire 5 months ago

TRGNF
0.00%
Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development

Strasbourg (France), Berlin (Germany), November 5, 2024, 7:30 a.m. CET—Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, and ProBioGen, a leading CDMO in biologics, vaccines and viral vectors, announce that the companies have entered into a license agreement for ProBioGen’s AGE1.CR.pIX® suspension cell line. This partnership aims to add value by combining ProBioGen’s specific production technology with the manufa

GlobeNewswire 5 months ago

TRGNF
0.00%
Transgene’s stock drops after Phase II cancer jab trial misses primary endpoint

Despite this setback, Transgene plans to explore the potential benefits of the vaccine in specific patient populations.

Clinical Trials Arena 5 months ago

TNG.PA

GLDAF
Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

Top line data show that the randomized Phase II study of TG4001 in combination with avelumab versus avelumab alone in patients with recurrent or metastatic HPV16-positive cervical and anogenital tumors did not meet the primary objective of improvement in progression-free survival Pre-planned subgroup analysis showed a positive efficacy trend in favor of the TG4001 containing regimen in patients with cervical cancer Transgene will complete full analysis of the data before deciding on the best way

GlobeNewswire 5 months ago

TRGNF
0.00%
Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024

Transgene will present median 24-month follow up data from patients enrolled in the Phase I trial evaluating the individualized cancer vaccine TG4050 in the adjuvant treatment of head and neck cancer Strasbourg, France, October 7, 2024, 8 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, will present a poster highlighting median 24-month follow up from the ongoing randomized Phase I trial of its indivi

GlobeNewswire 6 months ago

TRGNF
0.00%
Transgene SA (FRA:TGNA) (Q2 2024) Earnings Call Transcript Highlights: Promising Clinical Data ...

Transgene SA (FRA:TGNA) showcases significant advancements in clinical trials and confirms financial visibility until Q4 2025.

GuruFocus.com 6 months ago

TNG.PA
Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025

2024 Half-Year Results and Business Update Lead program TG4050 (individualized immunotherapy): – First signs of clinical benefit in adjuvant head and neck cancer reported at AACR 2024, paved the way for the start of Phase II part of randomized Phase I/II clinical trial in Q2 2024 – Median 24-month follow-up data to be presented in Q4 2024 BT-001 (oncolytic virus): Data presented at ESMO (Sept. 2024) showed promising antitumor activity in solid tumors that failed previous anti-PD(L)-1 treatment T

GlobeNewswire 6 months ago

TRGNF
0.00%
Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments

Preliminary data presented at ESMO 2024 demonstrate that BT-001 induces tumor regression in patients who failed previous anti-PD(L)-1 treatment In a patient with a heavily pretreated leiomyosarcoma, BT-001 was able to modulate the tumor microenvironment, turning a “cold” tumor to “hot”, enhancing the potential of T cell infiltration and a shift to PD(L)-1 positivity Early signs of efficacy with clinical responses observed with BT-001 in combination with KEYTRUDA® (pembrolizumab), in 2 of 6 patie

GlobeNewswire 6 months ago

TRGNF
0.00%
Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation

Newly appointed CMO, Dr. Emmanuelle Dochy, and newly appointed CSO, Dr. Maurizio Ceppi, bring a strong track record of advancing cancer immunotherapies and precision medicine through clinical development as Transgene progresses its innovative preclinical and clinical pipeline including personalized therapeutic cancer vaccine TG4050. Strasbourg, France, September 10, 2024, 7 : 30 AM CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for

GlobeNewswire 7 months ago

TRGNF
0.00%
Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024

BT-001 monotherapy showed stable disease and shrinkage of injected lesions in patients with advanced solid tumors. BT-001 in combination with KEYTRUDA® (pembrolizumab) showed promising efficacy data with partial responses in patients with relapsed and refractory advanced melanoma and leiomyosarcoma. BT-001 shows a favorable safety profile with minimal adverse events and no dose-limiting toxicities. Strasbourg, France, and Lund, Sweden, September 9, 2024, 7:00 am CET– Transgene (Euronext Paris: T

GlobeNewswire 7 months ago

TRGNF
0.00%
Transgene to Participate in HTID Conference and Investor Access Forum in Paris

Strasbourg, France, September 5, 2024, 5 : 45 PM CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announces that its management will participate in the following upcoming investor meetings taking place in Paris, France: 6th HealthTech Innovation Days (HTID), September 17 & 18, 2024Investor Access Forum, October 15 & 16, 2024 *** About Transgene Transgene (Euronext: TNG) is a biotechnology company focused o

GlobeNewswire 7 months ago

TRGNF
0.00%

Performance Overview

Return	TRGNF	CAC 40 (^FCHI)
YTD	-55.97%	-1.20%
1-Year	-56.79%	-8.07%
3-Year	-75.27%	+10.66%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Transgene SA (TRGNF)

Availability of Transgene’s 2024 Universal Registration Document (URD)

Transgene Appoints Chief Technical Officer (CTO) to Power Future Innovations

Transgene Achieves Key Milestones in 2024, Including Clinical Proof of Principle for Individualized Cancer Vaccine ̶ Strong Outlook for 2025

Transgene to Participate in Upcoming Investor Meetings

Transgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts

Transgene to Participate in the Biomed Forum Investor Conference

Transgene Announces Financial Calendar for 2025

Balance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2024

Transgene Reports Business, Pipeline and Financial Update for Q3 2024

Transgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024

Transgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development

Transgene’s stock drops after Phase II cancer jab trial misses primary endpoint

Transgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

Transgene to Present a Poster on Updated Data for TG4050 at SITC 2024

Transgene SA (FRA:TGNA) (Q2 2024) Earnings Call Transcript Highlights: Promising Clinical Data ...

Transgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025

Transgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments

Transgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation

Transgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024

Transgene to Participate in HTID Conference and Investor Access Forum in Paris

Performance Overview